Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial.

ABSTRACT:

Objectives

The BEST3 trial demonstrated the efficacy and safety of the Cytosponge-trefoil factor 3, a cell collection device coupled with the biomarker trefoil factor 3, as a tool for detecting Barrett's oesophagus, a precursor of oesophageal adenocarcinoma (OAC), in primary care. In this nested study, our aim was to understand patient experiences.

Design

Mixed-methods using questionnaires (including Inventory to Assess Patient Satisfaction, Spielberger State-Trait Anxiety Inventory-6 and two-item perceived risk) and interviews.

Outcome measures

Participant satisfaction, anxiety and perceived risk of developing OAC.

Setting

General practices in England.

Participants

Patients with acid reflux enrolled in the intervention arm of the BEST3 trial and attendi

SUBMITTER: Maroni R 

PROVIDER: S-EPMC8990713 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature